{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:19:52Z","timestamp":1768828792770,"version":"3.49.0"},"reference-count":8,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,13]]},"DOI":"10.1182\/blood.2023020813","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T15:41:32Z","timestamp":1690558892000},"page":"121-122","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab in PMBCL: can it go the distance?"],"prefix":"10.1182","volume":"142","author":[{"given":"Lisa","family":"Giulino-Roth","sequence":"first","affiliation":[{"name":"1Weill Cornell Medical College"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"2","key":"2023072815404998000_bib1","first-page":"141","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170","volume":"142","author":"Zinzani","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2023072815404998000_bib2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.2019001126","article-title":"Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma","volume":"134","author":"Mottok","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2023072815404998000_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"},{"issue":"34","key":"2023072815404998000_bib4","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"2023072815404998000_bib5","unstructured":"FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL. 2018. Accessed  May 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-treatment-relapsed-or-refractory-pmbcl."},{"issue":"33","key":"2023072815404998000_bib6","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 Study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2023072815404998000_bib7","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood-2018-04-791566","article-title":"How I treat primary mediastinal B-cell lymphoma","volume":"132","author":"Giulino-Roth","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2023072815404998000_bib8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/2\/121\/2067061\/blood_bld-2023-020813-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/2\/121\/2067061\/blood_bld-2023-020813-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T15:41:44Z","timestamp":1690558904000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/2\/121\/496697\/Pembrolizumab-in-PMBCL-can-it-go-the-distance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,7,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023020813","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,13]]}}}